Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Selling, General & Admin	30.71	30.09	21.91	15.66	11.29	8.9
Research & Development	10.43	11.91	14.82	17.66	12.24	8.81
Operating Expenses	41.14	42	36.73	33.32	23.53	17.71
Operating Income	-41.14	-42	-36.73	-33.32	-23.53	-17.71
Interest Expense	-0.17	-	-	-	-0.01	-0.02
Interest & Investment Income	0.17	0.76	1.18	0.25	0.26	0.07
Other Non Operating Income (Expenses)	-	-	-	-	-	0.11
EBT Excluding Unusual Items	-41.14	-41.24	-35.55	-33.06	-23.28	-17.55
Gain (Loss) on Sale of Assets	-	2.39	3.59	-	-	-
Other Unusual Items	-	-	-	-	0.23	-
Pretax Income	-41.14	-38.85	-31.97	-33.06	-23.05	-17.55
Income Tax Expense	0.94	0.58	0.58	0.58	-	-
Earnings From Continuing Operations	-42.07	-39.43	-32.54	-33.64	-23.05	-17.55
Minority Interest in Earnings	1.81	0.29	-	-	-	-
Net Income	-40.26	-39.14	-32.54	-33.64	-23.05	-17.55
Preferred Dividends & Other Adjustments	0.73	1.05	1.15	-	1.45	-
Net Income to Common	-40.99	-40.19	-33.69	-33.64	-24.51	-17.55
Shares Outstanding (Basic)	9	7	6	6	4	2
Shares Outstanding (Diluted)	9	7	6	6	4	2
Shares Change (YoY)	31.75%	11.16%	3.57%	34.52%	177.28%	94.25%
EPS (Basic)	-4.78	-5.97	-5.57	-5.76	-5.64	-11.20
EPS (Diluted)	-4.78	-5.97	-5.57	-5.76	-5.64	-11.20
Free Cash Flow	-20.58	-28.2	-29.06	-28.36	-24.26	-16.93
Free Cash Flow Per Share	-2.40	-4.19	-4.80	-4.85	-5.58	-10.81
EBITDA	-41.14	-41.99	-36.73	-33.31	-23.53	-17.71
D&A For EBITDA	0	0	0	0	0	0
EBIT	-41.14	-42	-36.73	-33.32	-23.53	-17.71

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q